Ariadne’s PathwayStudio® 4.0 Earns GeneChip-compatible™ Status
News May 02, 2006
Ariadne Genomics, Inc. has announced that it has joined the Affymetrix GeneChip-compatible Applications Program, which is designed to provide customers with a broad spectrum of software solutions for biomedical research and development.
Ariadne’s PathwayStudio® 4.0 pathway analysis software has earned GeneChip-compatible™ status.
As a GeneChip-compatible software provider, Ariadne is committed to integrating their entire pathway analysis product pipeline with the Affymetrix GeneChip technology.
PathwayStudio 4.0 (formerly marketed as PathwayAssist) allows life scientists to analyze and interpret gene expression microarray data in the context of biological pathways and to reconstruct regulatory networks from gene expression experiments.
The software comes with a database of over 1,000,000 molecular interaction facts extracted from the scientific literature and over 1,000 reconstructed pathways.
"We are delighted that PathwayStudio 4.0 has achieved GeneChip-compatible status with Affymetrix," said Dr. Ilya Mazo, president of Ariadne.
"Ariadne’s mission is to provide life scientists with tools and solutions to stimulate biomedical research and drug development."
"The integration between PathwayStudio and the Affymetrix GeneChip microarray platform is yet another vital milestone in the realization of our goal."
"Pathway-level annotation and functional analysis is fast becoming a standard part of gene expression microarray data analysis," said Steve Lincoln, vice president of Informatics at Affymetrix.
"The integration between the Affymetrix GeneChip platform and Ariadne’s PathwayStudio allows our mutual customers to extract the greatest value from their microarray data."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.